A Study of Belcesiran in Patients With AATLD

Clinical trial NCT04764448 · TERMINATED

Trial details

NCT number: NCT04764448
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Alpha 1-Antitrypsin Deficiency

Start date: 2021-02-12
Primary completion: 2023-12-08
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.